InvestorsHub Logo
Followers 55
Posts 2608
Boards Moderated 0
Alias Born 02/04/2014

Re: jaimejonas post# 39329

Tuesday, 08/11/2015 12:59:24 AM

Tuesday, August 11, 2015 12:59:24 AM

Post# of 144815
This is what I do know. 1Q2016 is 5 months away, not 9. A plan is not a promise and the company has always been forthright about needing to be GMP compliant prior to starting any trials.

Most recent update...

"Our plans are to begin the clinical trials by the fourth quarter of 2015 and possibly sooner, but the start date for the clinical trials will depend upon regulatory approval of Austrianova’s cGMP encapsulation facility in Bangkok, Thailand. That is the facility where our genetically modified living cells will be encapsulated using the Cell-in-a-Box® technology.”

http://www.pharmacytebiotech.com/chardan-releases-industry-report-covering-pharmacyte-biotech/

And from 2013.. Getting GMP approval has always been understood as a requirement to starting trials.

"Completing the GMP facility construction and establishing GMP standards for production of the encapsulated cells that are part of its pancreatic cancer treatment should serve as a catalyst for the Company and bring Nuvilex one step closer to advanced clinical trials."

http://www.marketwatch.com/story/establishing-a-good-manufacturing-practices-facility-serves-as-a-catalyst-for-nuvilex-2013-09-13
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PMCB News